Coloplast A/S

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Coloplast A/S (OTCPK:CLPBF) First Half 2022-2023 Earnings Conference Call May 11, 2023 5:00 AM ET Company Participants Kristian Villumsen – President and Chief Executive Officer Anders Lonning-Skovgaard – Chief Financial Officer Conference Call Participants Hassan Al-Wakeel – Barclays Veronika Dubajova – Citi Oliver Metzger – ODDO Christian Ryom – Danske Bank Maja Pataki – Kepler Cheuvreux Lisa Clive – Bernstein Niels Granholm-Leth – Carnegie Robert Davies – Morgan Stanley Julien Ouaddour – Bank of America Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Coloplast First Half 2022-2023 Earnings Release Conference Call.

Coloplast A/S (CLPBF) First Half 2022-2023 Earnings Call Transcript

Organic growth rates by business area: Ostomy Care 6%, Continence Care 6%, Voice and Respiratory Care 9% (2 months), Wound and Skin Care 13% (Wound Care 12%), and Interventional Urology 17%.

Coloplast B.V. - Announcement no.

H1 2022/23 Interim financial results, H1 2022/23 1 October 2022 - 31 March 2023 Coloplast delivered Q2 organic growth of 8 % and 28% EBIT margin 1) . Reported revenue in DKK was up by 10%.

Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23

Study results show that Coloplast's new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations, while Hollister's 2-eyelet catheter, VaPro™, achieved this in 52% of catheterisations.

Study shows significant improvement in bladder emptying with Coloplast's Luja™ compared to competitor catheter

Coloplast A/S (OTCPK:CLPBF) Q1 2023 Earnings Conference Call February 3, 2023 5:00 AM ET Company Participants Kristian Villumsen - President and CEO Anders Lonning-Skovgaard - CFO Conference Call Participants Hassan Al-Wakeel - Barclays Maja Pataki - Kepler Cheuvreux James Vane-Tempest - Jefferies Ed Ridley-Day - Redburn Christian Ryom - Danske Bank Veronika Dubajova - Citi Robert Davies - Morgan Stanley Operator Good morning, ladies and gentlemen. Thank you for standing by.

Coloplast A/S (CLPBF) Q1 2023 Earnings Call Transcript

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole.

Coloplast launches male catheter designed to reduce the risk of urinary tract infections

Coloplast A/S - Announcement no. 01/2023 – Interim Financial Report, Q1 2022/23

Articles of Association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 1 December 2022 are enclosed.

Coloplast A/S - Announcement no. 14/2022 - Articles of Association

Today, 1 December 2022, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted

Coloplast A/S - Announcement no. 13/2022 - Decisions at the Annual General Meeting 2022

Coloplast's SpeediCath ® Flex Set catheter developed for people living with bladder and urinary problems is now cleared in the U.S. and will be launched in November 2022.

Coloplast Launches New Catheter in the U.S.

Effective January 2, 2023,   Tommy Johns   will enter a new role as President & Senior Vice President of Coloplast's global Interventional Urology (IU) business, replacing Steve Blum, who has decided to retire at the end of 2022.

Coloplast appoints new President of its global Interventional Urology business

The Power Purchase Agreement (PPA) will contribute directly to the construction of a new large solar park and cover 100% of Coloplast's electricity consumption in Denmark from 2023 onwards.

Coloplast enters into Power Purchase Agreement with Better Energy

The Annual General Meeting of Coloplast A/S will be held on Thursday, 1 December 2022 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.

Coloplast A/S - Announcement no. 12/2022 - Notice of Annual General Meeting

Coloplast is a purpose-driven company: We make life easier for people living with intimate healthcare needs. In 2021/22, we continued to help more than two million users globally, but many user needs remain unmet across our business areas. We strive to build better standards of care, raise the bar with innovative products and create access for as many users as possible. We are building the consumer healthcare company of the future – enabling self-care for chronic users and supporting healthcare systems to meet, in a cost-effective way, increasing demand as the world population ages. This is a direct embodiment of the Coloplast mission and our key contribution to sustainable development.

Coloplast A/S - Announcement no. 11/2022 - Sustainability Report 2021/22

TROY, Mich., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer”) today announced the execution of a Loss Portfolio Transfer (LPT) reinsurance agreement with Fleming Reinsurance Ltd (“Fleming Re”). Through this transaction, Conifer secured $20 million of adverse development cover for accident years 2019 and prior.

Coloplast A/S - Announcement no. 10/2022 - Annual Report 2021/22 & Remuneration Report 2021/22

Coloplast A/S (OTCPK:CLPBF) Q4 2022 Earnings Conference Call November 7, 2022 9:00 AM ET Company Participants Kristian Villumsen - President & Chief Executive Officer Anders Lonning-Skovgaard - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Graham Doyle - UBS Martin Parkhoi - SEB Maja Pataki - Kepler James Vane-Tempest - Jefferies Mattias Häggblom - Handelsbanken Christian Ryom - Danske Bank Robert Davies - Morgan Stanley Julien Dormois - BNP Paribas Exane Niels Granholm - Carnegie Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Coloplast Full Year 2021-2022 Earnings Release Conference Call.

Coloplast A/S (CLPBF) Q4 2022 Earnings Call Transcript

Coloplast A/S Announcement no. 9/2022 - Full-Year Financial Results 2021/22

Coloplast is introducing the Saffron™ Fixation System designed for ease and reliability during pelvic floor reconstruction for women who suffer from pelvic organ prolapse (POP).

Coloplast launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23

Coloplast A/S - Meet the Management event

Coloplast A/S (OTCPK:CLPBF) Q3 2022 Earnings Conference Call August 17, 2022 9:00 AM ET CompanyParticipants Kristian Villumsen - President & CEO Anders Lonning-Skovgaard - EVP & CFO Conference Call Participants Patrick Wood - Bank of America Hassan Al-Wakeel - Barclays Martin Parkhøi - SEB Christian Ryom - Danske Bank Graham Doyle - UBS Mattias Häggblom - Handelsbanken Christoph Gretler - Credit Suisse David Adlington - JPMorgan Grace Lee - Jefferies Oliver Metzger - ODDO BHF Operator Welcome to the Coloplast interim financial statements for 9M 2021/22. [Operator instructions].

Coloplast A/S (CLPBF) CEO Kristian Villumsen on Q3 2022 Results - Earnings Call Transcript

Coloplast B.V. - Announcement no. 02/2022 - Interim Financial Report, 9M 2021/2022

Coloplast Finance B.V. - 9M Interim Financial Report 2021/2022

Coloplast A/S - Announcement no. 07/2022 - Interim Financial Report, 9M 2021/2022

Coloplast will host a Meet the Management event on Wednesday, 31 August 2022. Kindly register before 5 August 2022 for in-person attendance.

Coloplast A/S - Reminder: Coloplast's Meet the Management event on 31 August 2022 - register by 5 August 2022

Coloplast, a global medical device company and leader in intimate healthcare needs, has been awarded an AscenDrive agreement with Premier, Inc. AscenDrive is a national program designed to standardize the care delivery process and help drive the highest-level commitment and savings for members. Effective July 1, 2022, Coloplast is one of two suppliers awarded the AscenDrive contract for ostomy products.

News for Coloplast A/S Stock (CLPBY)